top of page

TELESCOPE

NEOADJUVANT PEMBROLIZUMAB AND CARBOPLATIN PLUS PACLITAXEL FOR STAGE I TRIPLE-NEGATIVE BREAST CANCER (TELESCOPE)

CLINICAL TRIAL DETAILS

THE STUDY WILL EVALUATE AN ANTHRACYCLINE-FREE REGIMEN FOR PATIENTS WITH T1CN0 TRIPLE-NEGATIVE BREAST CANCER. THE PRIMARY OBJECTIVE IS TO EVALUATE THE PATHOLOGICAL COMPLETE RESPONSE RATE DEFINED AS THE PERCENTAGE OF PATIENTS WITH YPT0/IS, YPN0 AT SURGERY BASED ON LOCAL ASSESSMENT.

TELESCOPE AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

N

SITES

Breast Cancer

​

30

II

Spain

Set-up

TRIAL OVERVIEW

home_fondo_you_barra.jpg
Luzern_edited_edited_edited_edited_edite

PRESS RELEASE

home_fondo_you_barra.jpg

-

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

ESMO 2025 poster


ESMO 2025 lay language summary

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

-

TRIAL SITES

home_fondo_you_barra.jpg
-
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page